肾功能与肝功能损害对zilurgisertib药代动力学的影响
本研究通过两项开放标签平行组试验,评估肾功能与肝功能损害对ALK-2抑制剂zilurgisertib药代动力学的影响;受试者单次口服200 mg并与健康对照匹配。结果显示轻度肾功能损害或中度肝功能损害时暴露量无变化,中度及以上肾功能损害暴露量增加30%–70%,重度肝功能损害增加25%;上述结果将结合正在进行的FOP关键试验确定的治疗指数指导给药。
要点
- 轻度肾功能损害或中度肝功能损害无需调整zilurgisertib暴露量
- 中度、重度肾功能损害及ESRD患者zilurgisertib暴露量升高,需关注给药策略
- 重度肝功能损害时zilurgisertib暴露量增加25%,用药需谨慎评估
核心结论
- 轻度肾功能损害或中度肝功能损害时zilurgisertib暴露量无变化。
- 中度或更严重肾功能损害时zilurgisertib暴露量增加30%–70%。
- 重度肝功能损害时zilurgisertib暴露量增加25%。
研究设计与样本
- 两项开放标签、平行组研究,肾功能或肝功能损害受试者与健康对照匹配。
- 受试者单次接受200 mg zilurgisertib,ESRD患者分别在血液透析前后给药。
- 血浆浓度经 validated assay 定量,药代参数采用非房室分析,Cmax、AUC0-t、AUC0-∞的GMR及90%CI经ANOVA比较。
主要发现
- 轻度肾功能损害:Cmax GMR 0.92(0.64-1.34),AUC0-∞ GMR 0.98(0.77-1.24)。
- 中度肾功能损害:Cmax GMR 1.22(0.92-1.63),AUC0-∞ GMR 1.64(1.28-2.10);重度:Cmax 1.00(0.74-1.35),AUC0-∞ 1.70(1.33-2.16)。
- ESRD透析前:Cmax GMR 1.17(0.91-1.49),AUC0-∞ 1.47(1.15-1.88);透析后:Cmax 1.32(1.00-1.75),AUC0-∞ 1.68(1.29-2.19)。
- 中度肝功能损害:Cmax GMR 1.06(0.80-1.42),AUC0-∞ 1.13(0.93-1.38);重度:Cmax 1.36(1.05-1.76),AUC0-∞ 1.25(1.06-1.48)。
关键数值与推荐
- 轻度肾功能损害或中度肝功能损害时zilurgisertib暴露量无变化。
- 中度或更严重肾功能损害时zilurgisertib暴露量增加30%–70%。
- 重度肝功能损害时zilurgisertib暴露量增加25%。
临床怎么用
- 轻中度肾功能损害或中度肝功能损害患者可参考常规剂量使用zilurgisertib。
- 中度及以上肾功能损害及重度肝功能损害患者需关注暴露量升高,给药方案应结合治疗指数评估。
- ESRD患者透析前后暴露量均升高,透析对清除的影响需结合关键试验数据综合判断。
局限性
- 治疗指数尚未确定,有待正在进行的FOP关键试验(NCT05090891)结果。
- 研究为单次给药药代动力学研究,未报告多次给药或长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Small-molecule activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics. METHODS: Two open-label, parallel-group studies were conducted. Participants with renal or hepatic impairment were matched with healthy controls and received a single 200-mg dose of zilurgisertib; those with end-stage renal disease (ESRD) received doses before and after haemodialysis. Plasma concentrations were quantified via validated assay; pharmacokinetic parameters were derived from non-compartmental analysis. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for Cmax, AUC0-t and AUC0-∞ were compared by ANOVA. RESULTS: Compared with matched controls, GMRs (90% CIs) for Cmax and AUC0-∞ were as follows: mild renal impairment, 0.92 (0.64-1.34) and 0.98 (0.77-1.24); moderate, 1.22 (0.92-1.63) and 1.64 (1.28-2.10); severe, 1.00 (0.74-1.35) and 1.70 (1.33-2.16), respectively. Among participants with ESRD, values were the following: before haemodialysis, 1.17 (0.91-1.49) and 1.47 (1.15-1.88); after, 1.32 (1.00-1.75) and 1.68 (1.29-2.19), respectively. Among participants with hepatic impairment, values were as follows: moderate, 1.06 (0.80-1.42) and 1.13 (0.93-1.38); severe: 1.36 (1.05-1.76) and 1.25 (1.06-1.48), respectively. CONCLUSIONS: Zilurgisertib exposure was unchanged with mild renal or moderate hepatic impairment, but increased by 30%-70% with moderate or more severe renal impairment and by 25% with severe hepatic impairment. These findings, alongside the therapeutic index, to be defined by the ongoing pivotal FOP trial (NCT05090891), will guide dosing in these populations.
引用
- Yang YO, Fang Y, Wang P, et al. Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. Br J Clin Pharmacol. 2025. PMID: 41360500. doi:10.1002/bcp.70372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。